), a leader in non-invasive monitoring technology for patient
care, recently revealed encouraging results from a multi-center
study of its rainbow Acoustic Monitoring (RAM). This positive
piece of news should boost investor confidence in the stock. The
company's stock returned a solid 22.3% to its investors on a
The study had analyzed the efficacy of RAM in comparison to
capnography (nasal cannula) in post-surgical pediatric patient
population. Results revealed that, despite having similar
accuracy like capnography, RAM displayed better patient
tolerance. The multi-center trial results were announced in
Pediatric Anesthesia and conducted by researchers at Cincinnati
Children's Hospital Medical Center, University of Arizona Medical
Center, and Children's Medical Center at Dallas.
RAM is used to measure respiratory rates in a non-invasive
manner (with a cloth adhesive sensor worn around the neck),
thereby allowing better comfort for children. Researchers
concluded that acoustic monitoring is a safer option to
continuously monitor respiration rate in pediatric patients.
Positive results from the clinical trial have highlighted MASI's
capabilities in developing products that are safe and
In September, MASI had entered into an agreement to sell its
Masimo Patient SafetyNet to U.S.-based Saint Alphonsus Regional
Medical Center. The 387-bed facility will install the device in
patient rooms on orthopedic, general surgery, and neurology
floors. Earlier, Masimo had forged an alliance with University
Children's Hospital in Basel, Switzerland. The hospital was the
first pediatric institution in the region to utilize the Masimo
Patient SafetyNet in its general wards.
Currently, Masim haso a Zacks Rank #2 (Buy). MASI had reported
earnings of 30 cents per share that beat the Zacks Consensus
Estimate by 3 cents in the last reported quarter. Its revenues
(including royalties) went up almost 12.0% to $137.4 million,
also exceeding the Zacks Consensus Estimate of $136 million.
Apart from MASI, other medical instrument stocks that warrant
a look include
Mindray Medical International Ltd
MAKO Surgical Corp.
). All these stocks carry a Zacks Rank #2 (Buy).
DEXCOM INC (DXCM): Free Stock Analysis Report
MAKO SURGICAL (MAKO): Free Stock Analysis
MASIMO CORP (MASI): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.